In conclusion, in the present phase 2, randomized double-blind controlled trial we show that TRC150094 did not improve insulin sensitivity and lipid metabolism or decrease hepatic steatosis in obese insulin resistant subjects with an increased cardiometabolic risk. This evidence concerns the gene INS and Hepatic steatosis.